Ias

THE CORPORATION IS ORGANIZED FOR CHARITABLE AND EDUCATIONAL PURPOSES, INCLUDING: (I) PROVIDING CRITICAL PLATFORMS FOR PRESENTING NEW RESEARCH, SHARING BEST PRACTICES, AND ADVANCING THE FIGHT AGAINST AIDS; AND (II) PROMOTING DIALOGUES, EDUCATION, AND NETWORKING TO HELP CLOSE GAPS IN KNOWLEDGE AND EXPERTISE AT EVERY LEVEL OF THE RESPONSE TO AIDS.

CONFERENCES: HIVR4P // VIRTUAL - THE 4TH HIV RESEARCH FOR PREVENTION CONFERENCE TOOK PLACE ON 27-28 JANUARY AND 3-4 FEBRUARY 2021, BRINGING TOGETHER OVER 1,800 DELEGATES FROM 92 COUNTRIES IN A VIRTUAL FORMAT TO FOCUS ON THE LATEST RESEARCH ON HIV PREVENTION SCIENCE. HIVR4P IS A BIENNIAL MEETING THAT BRINGS TOGETHER RESEARCHERS ON HIV VACCINES, MICROBICIDES, PRE-EXPOSURE PROPHYLAXIS (PREP), BASIC SCIENTISTS, SOCIAL AND BEHAVIOURAL SCIENTISTS, IMPLEMENTERS AND COMMUNITY ADVOCATES TO SHARE KNOWLEDGE AND DEVELOP RESEARCH COLLABORATIONS. THE CONFERENCE FEATURED OVER 400 PRESENTATIONS IN 23 ORAL ABSTRACT SESSIONS, FOUR PLENARIES, 10 SYMPOSIA, THREE ROUNDTABLES AND TWO RAPPORTEUR SESSIONS. EIGHTEEN SATELLITE MEETINGS TOOK PLACE ALONGSIDE THE CONFERENCE, AND 266 ON-DEMAND POSTERS WERE AVAILABLE THROUGH THE CONFERENCE PLATFORM. HIVR4P // VIRTUAL TOOK PLACE AT A TIME OF ENORMOUS CHALLENGES FOR HIV PREVENTION. COVID-19 AFFECTED MAJOR HIV PREVENTION CLINICAL STUDIES AND SLOWED DOWN ACCESS TO PREVENTION, TREATMENT AND CARE FOR HIV AND MANY RELATED CONDITIONS. THE CONFERENCE SHOWED THE ENORMOUS CONTRIBUTION THAT HIV RESEARCH HAS MADE TO THE DEVELOPMENT OF COVID-19 TREATMENTS AND VACCINES, BUILDING ON PRIOR HIV RESEARCH AND EXISTING TRIALS INFRASTRUCTURE. THE CONFERENCE ALSO SHOWED THAT DESPITE THE CHALLENGES ARISING FROM THE COVID-19 PANDEMIC, HIV PREVENTION RESEARCH HAS CONTINUED TO ADVANCE, BRINGING GREATER CHOICE OF PREVENTION METHODS CLOSER FOR MILLIONS.IAS 2021 SUMMARY: JUST OVER 6,000 HIV PROFESSIONALS AND COMMUNITY MEMBERS MET VIRTUALLY AND IN BERLIN, GERMANY, FOR IAS 2021, THE 11TH INTERNATIONAL AIDS SOCIETY CONFERENCE ON HIV SCIENCE, ON 18-21 JULY 2021. FOR THE SECOND YEAR, A CONFERENCE OF IAS THE INTERNATIONAL AIDS SOCIETY WAS DELIVERED AS A LARGELY VIRTUAL EVENT IN RESPONSE TO THE GLOBAL COVID-19 PANDEMIC. IAS 2021 WAS A HYBRID CONFERENCE, FEATURING LIVE BROADCAST SESSIONS IN BERLIN AND ONLINE LIVE AND RECORDED, ON-DEMAND SESSIONS.

GILEAD: THE GRANT OF US $50,000 FROM GILEAD SCIENCES SUPPORTED THE IAS TOWARDS AN HIV CURE INITIATIVE WHICH DRIVES CONCERTED EFFORTS TO ACCELERATE GLOBAL SCIENTIFIC RESEARCH AND ENGAGEMENT TOWARDS A CURE FOR HIV. THE INITIATIVE FOCUSES EFFORTS ON ADVANCING THE HIV CURE FIELD IN LOW- AND MIDDLE-INCOME SETTINGS AND FACILITATING INTERACTION WITH HIV AND OTHER BIOMEDICAL RESEARCH AREAS.